Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Immix Biopharma, Inc.NASDAQ: IMMX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $130.77K rose 121.0% year over year, behind the +164.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 44.3% from the prior quarter. Over 3 fiscal years it compounded at +454.8% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +121.0% toward the trailing-twelve-month pace of +164.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$130.77K+44.3% QoQ
Last fiscal yearDec 2025
$364.5K+215.9% YoY
LTMMar 2026
$398.22K+164.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+121.0%——
1 year+215.9%——
3-year CAGR+454.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
364.5K USD
Year-over-year change
+215.9%
4-year CAGR
+248.6%

Depreciation & Amortization vs competitors

How IMMX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +164.2% is the highest of 11, against a peer median of -1.3%.
  • Over three fiscal years its annual growth of +454.8% compares with a peer median of +11.9%.
IMMX Competitors
Depreciation & Amortization for IMMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$14.4M USD-22.3%+20.4%2.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$10M USD+0.0%+18.6%8.5%
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M USD-5.1%-15.4%4.5%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M USD+10.4%+5.3%3333.9%
IMMPImmutep LimitedFY2025A$2.13M AUD+6.0%+5.1%42.3%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.24M USD-26.3%-17.4%3.5%
ABVXAbivax S.A.FY2025€1.07M EUR-2.5%+30.3%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$1.03M USD+94.7%+56.5%196.6%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥1.03M CNY-95.7%-55.8%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$398.22K USD+164.2%+454.8%—
IMUXImmunic, Inc.LTM Mar 2026$158K USD+4.6%+29.7%—
Peer median (excluding IMMX) —-1.3%+11.9%8.5%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000364.5K
Gross Profit0000(364.5K)
Gross Margin—————
Research & Development126.53K4.2M8.74M11.29M16.26M
Selling, General & Admin1.23M4.02M7.41M11.38M13.7M
Operating Expenses1.35M8.22M16.14M22.67M26.85M
Depreciation & Amortization2.47K2.14K5.47K115.39K364.5K
EBITDA(24.2M)(8.22M)(15.56M)(21.54M)(29.04M)
EBITDA Margin—————
Operating Income(1.35M)(8.22M)(16.14M)(22.67M)(27.21M)
Operating Margin—————
Interest Income00572.01K1.02M555.53K
Interest Expense179.85K497000
Other Income / Expenses(23.03M)(497)572.01K1.02M(2.19M)
Income Before Tax(24.38M)(8.22M)(15.57M)(21.66M)(29.4M)
Pre-Tax Margin—————
Income Tax Expense6.01K10.27K26.42K41.04K37.72K
Net Income(24.38M)(8.23M)(15.43M)(21.61M)(29.44M)
Net Margin—————
EPS (Basic)(6.64)(0.59)(0.89)(0.76)(0.89)
EPS (Diluted)(6.64)(0.59)(0.89)(0.76)(0.89)
Weighted Avg Shares3.67M13.89M17.34M28.29M32.97M
Weighted Avg Shares (Diluted)3.67M13.89M17.34M28.29M32.97M

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.